Browse

A combination involving Tango’s experimental therapy appeared to boost response rates in a small clinical trial well beyond what would be expected, sparking a share surge.

Acquiring Vega Therapeutics, an offshoot of "hub-and-spoke" biotech Star Therapeutics, would give Incyte a medicine that’s in late-stage testing and designed to control bleeding.

The buyout hands J&J a technology that merges elements of two popular drugmaking methods: protein degraders and antibody-drug conjugates.